East Territory: Key areas are New York City, Boston, Baltimore, DC, and North Carolina
Serving as a field-based extension of the Medical Affairs Department, the Medical Science Liaison (MSL) will represent the Company and its novel oncology drug candidate, an oral small molecule histone deacetylase, or HDAC inhibitor in development as a combination therapy in multiple cancer indications, with an initial focus on tumors that have shown sensitivity to immunotherapy.
The MSL will deliver clinical and scientific data, and technical/practical education, to thought leaders, payers and other stakeholders within the medical oncology community. The MSL is responsible for developing, coordinating and assuring implementation of the Company’s corporate, scientific, and clinical strategies to these thought leaders within academic, clinical, and healthcare organizations. The MSL will build long-term peer-to-peer relationships and establish rapport with these thought leaders through highly scientific product and disease-related discussions. These scientific exchanges will support and/or expand current combination immuno-therapy therapeutic concepts, as well as ensure the safe and effective utilization of Company product(s).
Additionally, the MSL will supports research initiatives and investigator-sponsored studies and participate in and contribute to projects and initiatives that increase the value and productivity of the Medical Affairs team.